Review links iron-dependent cell death to pathogenesis of Friedreich's Ataxia

Published in the open-access journal Ferroptosis and Oxidative Stress, the review by Giovanni Cravin and Giorgio Cozza from the University of Padua examines the growing evidence linking ferroptosis to the pathogenesis of Friedreich's Ataxia (FRDA), a rare inherited neurodegenerative disease characterized by progressive neurological decline, cardiomyopathy, and premature mortality.

Friedreich's Ataxia is caused by deficiency of frataxin, a mitochondrial protein essential for iron–sulfur cluster biogenesis and cellular energy metabolism. Loss of frataxin disrupts mitochondrial function, promotes oxidative stress, and leads to abnormal iron accumulation-hallmarks that closely resemble the molecular conditions known to trigger ferroptosis.

Ferroptosis is an iron-dependent form of regulated cell death driven by excessive lipid peroxidation. Although initially studied primarily in cancer biology, ferroptosis has increasingly been implicated in neurodegenerative disorders, where dysregulated iron metabolism and oxidative damage contribute to neuronal loss. According to the authors, FRDA may represent one of the most compelling examples of a disease in which multiple ferroptosis-promoting mechanisms converge.

The review summarizes how frataxin deficiency creates a cellular environment highly susceptible to ferroptotic damage. Mitochondrial iron overload, impaired antioxidant defenses, reactive oxygen species accumulation, and lipid peroxidation collectively establish conditions that may accelerate degeneration of both nervous and cardiac tissues.

Importantly, the article moves beyond disease mechanisms to examine therapeutic opportunities. The authors discuss a broad range of pharmacological strategies that could modulate ferroptotic pathways in FRDA, including iron chelators, antioxidants, lipid peroxidation inhibitors, mitochondrial-targeted therapies, and emerging ferroptosis-specific interventions. Several of these approaches have already demonstrated encouraging results in preclinical studies, suggesting that ferroptosis-targeted therapies may offer new avenues for disease modification.

The review also highlights a major shift in the field. Rather than viewing iron accumulation and oxidative stress as isolated pathological features, researchers are increasingly recognizing them as interconnected components of a ferroptotic network. Understanding this network could help explain disease progression and reveal new therapeutic vulnerabilities.

As interest in ferroptosis continues to expand beyond oncology, Friedreich's Ataxia may provide an important model for understanding how ferroptotic mechanisms contribute to human neurodegenerative disease. The authors argue that integrating advances in ferroptosis biology with FRDA research could accelerate the development of more effective therapies for a disease that currently lacks curative treatment options.